CNTB

Insider Trades

Name	Value	Action	Price	Current Price
Huang JamesDirector $372k150k shares BuyMay 29, 2026 $2.48 --
Huang JamesDirector $4.0M1.2M shares BuyMar 31, 2026 $3.45 --

News

globenewswire.comConnect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthmaglobenewswire.comJun 17

marketbeat.comConnect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026marketbeat.comMay 22

globenewswire.comConnect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conferenceglobenewswire.comMay 12

globenewswire.comConnect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 12

seekingalpha.comConnect Biopharma: New Market Opportunity In The Emergency Settingseekingalpha.comApr 29

Trade CNTB

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

CEO: Barry D. Quart
IPO Date: Mar 19, 2021

Market Data

Open: $2.08
High: $2.16
Low: $1.93
Volume: 203.5K
Avg Volume: 298.6K
52W High: $3.82
52W Low: $0.91

Valuation

Market Cap: $126M
Enterprise Value: $88M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-52M
Revenue: $64k
Net Income: $-55M
Cash: $38M
Debt: $690k

Events

EarningsAug 12

EPS est. -0.32